Date: 21/04/202	Date: <u>21/04/2022</u>			
Your Name:	DR ELIZABETH A CORLEY			
Manuscript Title	THE ROLE OF SYSTEMIC THERAPY IN PAEDIATRIC MELANOMA: A REVIEW			
Manuscript number (if known): <u>PM-22-5</u>				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	_x_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	Royal Marsden Cancer Charity	Salary funded through Royal Marsden Cancer Charity
	in item #1 above).		
3	Royalties or licenses	x_None	
4	Consulting fees	_x_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	_x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_xNone	
11	Stock or stock options	_x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None	
13	Other financial or non- financial interests	X_None	

Salary funded through Royal Marsden Cancer Charity

No other conflicts of interest to declare

Please place an "X" next to the following statement to indicate your agreement:

__X_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 21/04/2022		
Your Name: DR A	ndreas Michael Schmitt	
Manuscript Title:	THE ROLE OF SYSTEMIC THERAPY IN PAEDIATRIC MELANOMA: A REVIEW	
Manuscript number (i	f known): <u>PM-22-5</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<u>A</u>		Time frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	yes	AM Schmitt has received an educational grant from Janssen-Cilag AG.
3	Royalties or licenses		
4	Consulting fees	x_None	

5	Payment or honoraria for lectures, presentations,	none	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	Yes	AM Schmitt has received support for conference attendance from Novartis.
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or	x_None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_x_None	
11	Stock or stock options	_x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
13	Other financial or non-	X_None	
	financial interests		

AM Schmitt has received an educational grant from Janssen-Cilag AG. AM Schmitt has received support for conference attendance from Novartis.

Please place an "X" next to the following statement to indicate your agreement:

 $_X_I$ certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:	24 th April 2022	
Your Name:	Andrew J.S. Furness	
Manuscript Title: The Role of System	ic Therapy in Paediatric Cut	taneous Melanoma: A Review
Manuscript number (if known):	PM-22-5	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees		
5	Payment or honoraria for	BMS	Renumeration for speaking duties at educational event
	lectures, presentations,	Esai	Renumeration for speaking duties at educational event
	speakers bureaus,	lpsen	Renumeration for speaking duties at educational event

6	manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
0	pending		
9	Participation on a Data Safety Monitoring Board or	GSK	Renumeration for advisory board participation re. Letecel
	Advisory Board	Immunocore	Renumeration for advisory board participation re. tebentafusp
		Achilles Therapeutics	Renumeration for advisory board participation re. tissue procurement within Achilles clinical trials
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	British Society of Bone Marrow Transplantation and Cellular Therapy (BSBMTCT)	Solid Tumour Cell Therapy subgroup lead
		ESMO	Faculty – Cancer Immunology and Immunotherapy & Investigational Immunotherapy groups
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Andrew Furness (AF) has received honoraria in terms of renumeration for speaking duties at educational events from BMS, Eisai and Ipsen. AF has participated in both paid and unpaid advisory boards for GSK, Achilles Therapeutics and Immunocore. AF has unpaid leadership/society/committee roles within the BSBMTCT and ESMO.

Please place an "X" next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	24 th April 2022	
Your Name:	Dr Julia Chisholm	
Manuscript Title: The Role of Systemic T	Гherapy in Paediatric Cutaneous Melanoma: A Revie	w
Manuscript number (if known):	PM-22-5	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Royal Marsden Cancer Charity	Salary funding
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	

	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	-		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests		

Salary partially funded through Royal Marsden Cancer Charity

Please place an "X" next to the following statement to indicate your agreement:

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.